Form 4 for VYGR Voyager Therapeutics, Inc.
Accepted 2023-01-10 00:00:00 ET · period of report 2023-01-06 · accession 0001104659-23-002718 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-10 | 2022-12-31 | VYGR | Carter Todd Alfred | CSO | A - Grant | $5.17 | +388 | 36.6K | +1% | +$2,006 | |
| 2023-01-10 | 2023-01-06 | VYGR | Carter Todd Alfred | CSO | S - Sale | $6.41 | -388 | 36.2K | -1% | -$2,487 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-31 | A | A | 388 | $5.17 | 36,582 | D | — | — | (F1) Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d). |
| 2 | Common | Common Stock | 2023-01-06 | S | D | 388 | $6.41 | 36,194 | D | — | — |